Team:Wageningen UR

From 2012.igem.org

(Difference between revisions)
Line 27: Line 27:
   </div>
   </div>
    
    
 +
  <div class="homeLB">
 +
  <div class="col">
 +
    <h2 class="ulc1">The Team</h2>
 +
    <p><a href="https://2012.igem.org/Team:Wageningen_UR/Team" title="Meet the Team" class="bigbutton bTeam">Meet the team!</a></p>
 +
  </div>
 +
  </div>
 +
  </div>
  </div>
    
    
Line 42: Line 49:
<h2 class="ulc3">The Constructor</h2>
<h2 class="ulc3">The Constructor</h2>
<p><a href="https://2012.igem.org/Team:Wageningen_UR/TheConstructor" title="The Constructor" class="bigbutton bConstructor">An application that assists you in creating your cloning strategies for your iGEM project.</a></p>
<p><a href="https://2012.igem.org/Team:Wageningen_UR/TheConstructor" title="The Constructor" class="bigbutton bConstructor">An application that assists you in creating your cloning strategies for your iGEM project.</a></p>
-
 
-
<br />
 
-
 
-
<h2 class="ulc1">The Team</h2>
 
-
<p><a href="https://2012.igem.org/Team:Wageningen_UR/Team" title="Meet the Team" class="bigbutton bTeam">Meet the team!</a></p>
 
     </div>
     </div>

Revision as of 15:23, 25 October 2012


Project Overview

A standardized tool for site specific drug delivery using Virus-Like Particles

Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.

The Team

Meet the team!